The first drug that treats the root cause of cystic fibrosis won approval Tuesday, offering a life-changing treatment for a handful of patients with the deadly illness, and broader hope for thousands more patients suffering from the inherited disease.
The Food and Drug approved Vertex Pharmaceutical's Kalydeco (kuh-LYE-deh-koh) to improve lung function in patients with a rare variant of the disease that affects just 1,200 people in the U.S. or about 4 percent of the affected population nationwide.
These patients have a protein defect that prevents their cells from properly absorbing and excreting salt and water.
About 30,000 Americans live with cystic fibrosis, a disease that causes sticky mucus buildup in the lungs and other organs, leading to infections, digestive problems and death in young adulthood.
Cystic fibrosis is one of the most common chronic diseases in children. It is passed down through families. 40 years ago, children with CF were not likely to survive past their teen years. Today, many do, although they need continuing medical care.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
